Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Dr. Zakashansky on Maintenance Olaparib in Relapsed BRCA1/2+ Ovarian Cancer

July 28th 2020

Konstantin Zakashansky, MD, discusses data with olaparib in advanced, recurrent, platinum-sensitive, BRCA-mutated ovarian cancer.

ATHENA Trial of Maintenance Rucaparib/Nivolumab in Ovarian Cancer Completes Target Enrollment

July 23rd 2020

The pivotal phase 3 ATHENA trial, which will examine the safety and efficacy of rucaparib in combination with nivolumab as maintenance treatment following response to front-line platinum-based chemotherapy in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, has completed target enrollment.

Dr. Arend on Unmet Needs in Platinum-Resistant Ovarian Cancer

July 22nd 2020

Rebecca C. Arend, MD, discusses the unmet needs in of patients with platinum-resistant ovarian cancer.

Dr. O’Malley on the Activity of Mirvetuximab Soravtansine in Ovarian Cancer

July 21st 2020

David O'Malley, MD, discusses the activity of the investigational antibody-drug conjugate mirvetuximab soravtansine in ovarian cancer.

Upcoming Clinical Trials for Ovarian Cancer

July 20th 2020

Emerging Therapies in Recurrent Ovarian Cancer

July 20th 2020

Antibody Drug Conjugates for Ovarian Cancer

July 20th 2020

Neoadjuvant Therapy Versus Surgery for Ovarian Cancer

July 20th 2020

New Data for Secondary Surgery in Ovarian Cancer

July 20th 2020

PARP Inhibitors in Recurrent Ovarian Cancer

July 20th 2020

Expert Approaches for Treating Recurrent Ovarian Cancer

July 20th 2020

Emerging Combinations in the Frontline Setting of Ovarian Cancer

July 20th 2020

Patient Preference for Treatment in Ovarian Cancer

July 20th 2020

PAOLA-1 Study Surgical Subset for Ovarian Cancer

July 20th 2020

NCCN Guidelines and FDA Approvals for Treating Ovarian Cancer

July 20th 2020

Personalized Dosing of Niraparib in Ovarian Cancer

July 20th 2020

Treating Homologous Recombination Proficient Ovarian Cancer

July 20th 2020

Treating BRCA+ Ovarian Cancer

July 20th 2020

Need for Frontline Comparison Trials in Ovarian Cancer

July 20th 2020

Impact of HRD Status on Frontline Treatment of Ovarian Cancer

July 20th 2020